HLA-C and neoplasm: In 2016, Eric Tran et al reported that they identified a polyclonal CD8+ T-cell response against mutant KRAS G12D in tumor-infiltrating lymphocytes, and observed regression of lung metastases after the infusion of HLA-C*08:02-restricted tumor-infiltrating lymphocytes that were composed of four different T-cell clonotypes that specifically targeted KRAS G12D 53.